Who are Liposomal daunorubicin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cipro, Epirubicin (E), Pegylated liposomal doxorubicin hydrochloride, Daunorubicin or Idarubicin, epirubicin - cyclophosphamide / docetaxel + lapatinib, Epirubicin Injectable Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/liposomal-daunorubicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Liposomal daunorubicin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liposomal daunorubicin (Liposomal daunorubicin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthracycline chemotherapy agent. Area: Oncology.

phase 3 Anthracycline chemotherapy agent Topoisomerase II, DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Liposomal daunorubicin (Liposomal daunorubicin) — University of Birmingham. Liposomal daunorubicin is an anthracycline chemotherapy agent encapsulated in liposomes that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cancer cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Liposomal daunorubicin TARGET	Liposomal daunorubicin	University of Birmingham	phase 3	Anthracycline chemotherapy agent	Topoisomerase II, DNA
Cipro	ciprofloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Epirubicin (E)	Epirubicin (E)	Eye & ENT Hospital of Fudan University	marketed	Anthracycline topoisomerase II inhibitor	Topoisomerase II, DNA
Pegylated liposomal doxorubicin hydrochloride	Pegylated liposomal doxorubicin hydrochloride	M.D. Anderson Cancer Center	marketed	Anthracycline chemotherapy (liposomal formulation)	Topoisomerase II, DNA
Daunorubicin or Idarubicin	Daunorubicin or Idarubicin	Stichting Hemato-Oncologie voor Volwassenen Nederland	phase 3	Anthracycline topoisomerase II inhibitor	Topoisomerase II, DNA
epirubicin - cyclophosphamide / docetaxel + lapatinib	epirubicin - cyclophosphamide / docetaxel + lapatinib	GBG Forschungs GmbH	phase 3	anthracycline antibiotic, alkylating agent, taxane, tyrosine kinase inhibitor	topoisomerase II, DNA, microtubules, HER2, EGFR
Epirubicin Injectable Product	Epirubicin Injectable Product	The First Affiliated Hospital with Nanjing Medical University	phase 3	Anthracycline topoisomerase II inhibitor	Topoisomerase II, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-04-21 — Cipro · 11369566 · Formulation · US
2029-04-21 — Cipro · 9603796 · Compound · US
2029-04-21 — Cipro · 9205048 · Method of Use · US
2029-12-11 — Cipro · 9233068 · Formulation · US
2030-04-27 — Cipro · 8318817 · Method of Use · US
2035-07-01 — Cipro · 9220796 · Formulation · US
2037-11-12 — Cipro · 11040004 · Method of Use · US
2038-11-27 — Cipro · 11246863 · Formulation · US

Sponsor landscape (Anthracycline chemotherapy agent class)

Assistance Publique Hopitaux De Marseille · 1 drug in this class
Institute of Hematology & Blood Diseases Hospital, China · 1 drug in this class
Italian Sarcoma Group · 1 drug in this class
University of Birmingham · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Liposomal daunorubicin — Competitive Intelligence Brief. https://druglandscape.com/ci/liposomal-daunorubicin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab